InvestorsHub Logo

$heff

03/02/17 11:56 PM

#96490 RE: $heff #96102

$AGIO $CELG.. FDA Accepts NDA and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation. Pdufa Aug. 30 17'